author-photo

Matthew Wongchenko

Genentech

97

Papers

2607

Citations

Citation Trend

Filter By

Papers (72) Sort By

Journal Conference Others

Tumour gene expression signature in primary melanoma predicts long-term outcomes

2021 Nature Communications
Show All
- Source
- Cite
- Save
Citations (6)
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)
PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

2021 The Lancet
Show All
- Source
- Cite
- Save
Citations (9)
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS5-06: Prospective testing forPIK3CA/AKT1/PTENalterations in tumor tissue from 1440 patients with advanced hormone receptor-positive HER2-negative breast cancer (HR+/HER2- BC) or triple-negative breast cancer (TNBC) screened for the IPATunity130 randomized phase 3 trial

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PO-101: Transcriptional heterogeneity in lung adenocarcinoma reveals distinct therapeutic vulnerabilities

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)

2020
Show All
- Source
- Cite
- Save
Citations (3)
283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)